Show simple item record

dc.contributor.authorPizarro-Guajardo, M.
dc.contributor.authorDíaz-González, F.
dc.contributor.authorÁlvarez-Lobos, M.
dc.contributor.authorParedes-Sabja, D.
dc.date.accessioned2018-02-01T15:26:33Z
dc.date.available2018-02-01T15:26:33Z
dc.date.issued2017-08
dc.identifier.citationFrontiers in Cellular and Infection Microbiology. Volume 7, Issue August 2017, Article number 365es_CL
dc.identifier.issn2235-2988
dc.identifier.otherDOI: 10.3389/fcimb.2017.00365
dc.identifier.urihttp://repositorio.unab.cl/xmlui/handle/ria/5234
dc.descriptionIndexación: Web of Science; Scopus.es_CL
dc.description.abstractClostridium difficile infection (CDI) are the leading cause of world-wide nosocomial acquired diarrhea. The current main clinical challenge in CDI is the elevated rate of infection recurrence that may reach up to 30% of the patients, which has been associated to the formation of dormant spores during the infection. We sought to characterize the effects of oral administration of specific anti-spore IgY in mouse models of CDI and recurrent CDI. The specificity of anti-spore IgY was evaluated in vitro. In both, initiation mouse model and recurrence mouse model, we evaluated the prophylactic and therapeutic effect of anti-spore IgY, respectively. Our results demonstrate that anti-spore IgY exhibited high specificity and titers against C. difficile spores and reduced spore adherence to intestinal cells in vitro. Administration of anti-spore IgY to C57BL/6 mice prior and during CDI delayed the appearance of the diarrhea by 1.5 day, and spore adherence to the colonic mucosa by 90%. Notably, in the recurrence model, co-administration of anti-spore IgY coupled with vancomycin delayed the appearance of recurrent diarrhea by a median of 2 days. Collectively, these observations suggest that anti-spore IgY antibodies may be used as a novel prophylactic treatment for CDI, or in combination with antibiotics to treat CDI and prevent recurrence of the infection.es_CL
dc.description.urihttps://www.frontiersin.org/articles/10.3389/fcimb.2017.00365/full
dc.language.isoenes_CL
dc.publisherFrontiers Mediaes_CL
dc.subjectChicken immunoglobulin IgYes_CL
dc.subjectClostridium difficile sporeses_CL
dc.subjectExosporiumes_CL
dc.subjectGerminationes_CL
dc.subjectImmunotherapyes_CL
dc.subjectPassive immunizationes_CL
dc.subjectRecurrent CDIes_CL
dc.subjectSporulationes_CL
dc.titleCharacterization of Chicken IgY Specific to Clostridium difficile R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Diseasees_CL
dc.typeArticlees_CL


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record